Wall Street brokerages expect Hill-Rom Holdings, Inc. (NYSE:HRC) to report earnings of $0.98 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Hill-Rom’s earnings. The highest EPS estimate is $0.99 and the lowest is $0.98. Hill-Rom reported earnings of $0.92 per share in the same quarter last year, which suggests a positive year over year growth rate of 6.5%. The firm is expected to report its next quarterly earnings results on Friday, January 25th.
On average, analysts expect that Hill-Rom will report full-year earnings of $5.13 per share for the current financial year, with EPS estimates ranging from $5.09 to $5.16. For the next financial year, analysts anticipate that the firm will report earnings of $5.73 per share, with EPS estimates ranging from $5.68 to $5.77. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Hill-Rom.
Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, November 2nd. The medical technology company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.12. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. The firm had revenue of $759.20 million during the quarter, compared to analysts’ expectations of $750.90 million. During the same quarter last year, the firm earned $1.32 earnings per share. The business’s revenue for the quarter was up 2.8% on a year-over-year basis.
HRC has been the subject of a number of analyst reports. KeyCorp boosted their price target on Hill-Rom from $97.00 to $115.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 17th. Raymond James boosted their price target on Hill-Rom from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, July 30th. Northcoast Research reaffirmed a “buy” rating and issued a $104.00 price target on shares of Hill-Rom in a research report on Tuesday, July 31st. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a research report on Tuesday, July 31st. Finally, Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Hill-Rom presently has an average rating of “Buy” and an average target price of $100.00.
Institutional investors have recently bought and sold shares of the company. Vigilant Capital Management LLC bought a new position in shares of Hill-Rom in the second quarter worth about $109,000. Flagship Harbor Advisors LLC bought a new position in shares of Hill-Rom in the second quarter worth about $173,000. CAPROCK Group Inc. bought a new position in shares of Hill-Rom in the third quarter worth about $211,000. Johanson Financial Advisors Inc. bought a new position in shares of Hill-Rom in the third quarter worth about $221,000. Finally, CIBC Asset Management Inc bought a new position in Hill-Rom during the second quarter valued at about $203,000. Institutional investors and hedge funds own 80.65% of the company’s stock.
Shares of NYSE:HRC traded down $0.87 on Friday, reaching $97.15. The company had a trading volume of 501,078 shares, compared to its average volume of 701,448. Hill-Rom has a twelve month low of $75.68 and a twelve month high of $98.96. The stock has a market capitalization of $6.45 billion, a P/E ratio of 20.45, a P/E/G ratio of 1.34 and a beta of 0.90. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.74 and a quick ratio of 1.30.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Shareholders of record on Friday, December 14th will be given a $0.20 dividend. The ex-dividend date is Thursday, December 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.82%. Hill-Rom’s dividend payout ratio is currently 16.84%.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: What are the benefits of a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.